This technology features a composition for preventing and treating skin damage, containing one or more active ingredients from Lactococcus chungangensis—a Gram-positive lactic acid bacterium isolated from kimchi or wastewater treatment plants—including its strains, cultures, heat-killed cells, or fermented products. It is formulated for pharmaceutical use in treating wounds, diabetic ulcers, and scarring, as well as for use in quasi-drugs, cosmetics for wrinkles, loss of elasticity, and pigmentation, and food compositions.
When skin is damaged, the stratum corneum and lipid barrier break down, leading to a sharp increase in transepidermal water loss, which causes dryness, wrinkles, itching, and bacterial inflammation. Inflammatory cytokines like IL-6 and TNF-α mediate inflammatory diseases such as contact dermatitis and psoriasis. Rapid wound healing requires a swift proliferative phase where fibroblasts migrate and multiply to produce collagen, yet there has been a lack of safe, highly effective new materials for wound healing and skin improvement.
This technology utilizes the CAU 1447 strain (deposit number KCTC 13873BP) and can be formulated as heat-killed cells, eliminating the storage and stability challenges associated with live bacteria. In animal models, this composition prevented pathogenic infection, promoted the secretion of growth factors and chemokines that drive skin regeneration and angiogenesis, and accelerated wound healing by modulating the skin microbiome. It can be applied to diabetic foot ulcer ointments, scar-improvement sprays and patches, and functional cosmetics for wrinkles and pigmentation, offering a dual approach of infection control and tissue regeneration by restoring skin microbial balance.
This invention was developed with support from the Ministry of Agriculture, Food and Rural Affairs for the development of probiotic materials to improve stress and type 2 diabetes using microbiome analysis technology.
N/A
